Segment Information - Net Revenue and Segment Ebitda (Detail) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017
Segment Reporting, Revenue Reconciling Item [Line Items]
Impairment Charges And Gain Loss On Sale Of Assets		$ (0.2)	$ (1.8)	$ (4.4)	$ (2.3)
Net revenue		627.9	532.6	1,778.1	1,458.5
Segment EBITDA		114.3	93.8	281.5	241.7
Inter-segment revenue elimination		(18.6)	(9.4)	(45.8)	(29.1)
Equity compensation		(5.6)	(4.6)	(21.1)	(16.4)
Restructuring and other special items	[1]	(10.5)	(8.5)	(34.7)	(21.6)
Other income (expense), net	[2]	(10.5)	(7.3)	(29.8)	(3.4)
Non-allocated corporate costs, net		(10.7)	(10.6)	(29.7)	(29.2)
Total unallocated costs	[3]	(37.5)	(32.8)	(119.7)	(72.9)
Softgel Technologies [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Net revenue		228.5	209.9	676.3	598.2
Segment EBITDA		52.2	51.4	137.4	125.3
Drug Delivery Solutions [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Net revenue		313.6	234.6	824.8	639.9
Segment EBITDA		80.8	59.5	209.3	151.5
Clinical Supply Services [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Net revenue		104.4	97.5	322.8	249.5
Segment EBITDA		$ 18.8	$ 15.7	$ 54.5	$ 37.8

[1] {F|ahBzfndlYmZpbGluZ3MtaHJkcmoLEgZYTUxEb2MiXlhCUkxEb2NHZW5JbmZvOjIyOTY1ZDVkMTJkOTRiYzhiY2Y5MjkzMzYyYWIyMmVjfFRleHRTZWxlY3Rpb246MzVEOUExMzEwRjAwNTA0Njk4QzJCMzM4NUE1QTIwODMM}

[2] s

[3] {F|ahBzfndlYmZpbGluZ3MtaHJkcmoLEgZYTUxEb2MiXlhCUkxEb2NHZW5JbmZvOjIyOTY1ZDVkMTJkOTRiYzhiY2Y5MjkzMzYyYWIyMmVjfFRleHRTZWxlY3Rpb246QzYxRUYyMzE2NjQ2NTczQzg0OTAxODYxMkQzRDk2QzkM}